H. W. Pauls* et al. (University Health Network, Toronto, Canada and Celtic Catalysts, Dublin, Ireland)
The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspirocyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent

Synthesis of Polo-Like Kinase 4 Inhibitor CFI-400945

**Significance:** CFI-400945 is an inhibitor of Polo-like kinase 4 (PLK4) that is a lead for the treatment of various cancers. The synthesis depicted features a diastereoselective one-pot double SN2 displacement reaction (E → H) for the creation of the cyclopropane ring. The authors propose that the stereoselectivity of the cyclopropanation is a consequence of π–π interactions that stabilize conformer G.

**Comment:** Attempted hydrogenolysis of the benzyl protecting groups from a close relative of H was accompanied by partial ring opening of the cyclopropane. However, the benzyl groups were removed cleanly using potassium tert-butoxide in an oxygen-saturated solution in THF and DMSO (R. M. Williams, E. Kwast Tetrahedron Lett. 1989, 30, 451).

**SYNFACTS Contributors:** Philip Kocienski

SYNFACTS 2015, 11(4), 0345 Published online: 18.03.2015
DOI: 10.1055/s-0034-1380330; Reg-No.: K00915SF

© THIEME STUTTGART • NEW YORK